

Casdozokitug, a First-in-Class, Anti-IL-27 Antagonistic Antibody, Treatment Promotes NK and T cell **Activation and Inflammatory Response in Phase I Study of Cancer Patients with Advanced Solid Tumors**


Sruthi Ravindranathan, Daniel J Chin, Narendiran Rajasekaran, Kate Widmann, Jonathan A Hill, Helen Tang, Koho lizuka, Rosh Dias, Theresa LaVallee, Varun N Kapoor


Coherus Biosciences, Redwood City, CA

- comprised of IL-27p28 and EBI3 subunits.
- effector function.
- antitumor immune responses.
- high-affinity human IgG1 antibody, which neutralizes IL-27, promotes immune activation, and stimulates antitumor response.
- antitumor activity (PR) as a single agent and in combination with PD-1 blockade in indications
- bevacizumab in patients with untreated locally advanced or metastatic HCC.









statistically significant.

